CEO Stephen Yoder (Pieris)

Pieris fi­nal­ly vaults FDA hold on next-gen sol­id tu­mor hunter, clear­ing the path for mid-stage tri­al

Fi­nal­ly freed from the re­straints of a par­tial FDA clin­i­cal hold on its lead HER2-pos­i­tive sol­id tu­mor can­di­date, Pieris Phar­ma­ceu­ti­cals is now rac­ing to­ward Phase II.

The FDA slapped a par­tial hold on Pieris’ PRS-343 back in Ju­ly, re­strict­ing the biotech from en­rolling new pa­tients in a Phase I tri­al. While Pieris was al­lowed to con­tin­ue dos­ing pa­tients who were al­ready en­rolled, the agency re­quest­ed they con­duct an ad­di­tion­al “in-use and com­pat­i­bil­i­ty study” be­fore re­cruit­ing any more.

PRS-343 con­sists of a 4-1BB-tar­get­ing An­ti­calin pro­tein and a HER2-tar­get­ing an­ti­body. It’s a frozen for­mu­la­tion that’s re­moved from a freez­er and pre­pared for IV in­fu­sion at the tri­al site, CEO Stephen Yo­der said.

“There was a re­quest from FDA to test the mol­e­cule, the drug prod­uct, un­der var­i­ous con­di­tions in­clud­ing stress con­di­tions to show that it has a very ro­bust sta­bil­i­ty pro­file, giv­en the vari­abil­i­ty that can hap­pen in the dif­fer­ent clin­i­cal sites,” Yo­der told End­points. 

At the time, the biotech had en­rolled pa­tients in the two high­est-dose co­horts — 8 mg/kg and 18 mg/kg — and in com­bi­na­tion stud­ies with Tecen­triq un­der a drug sup­ply agree­ment with Roche.

At vir­tu­al ES­MO 2020, Pieris said the drug showed a “durable clin­i­cal ben­e­fit in the ac­tive dose co­horts, in­clud­ing a con­firmed com­plete re­sponse, in heav­i­ly pre-treat­ed pa­tients across mul­ti­ple HER2-pos­i­tive tu­mor types” in Phase I monother­a­py and Tecen­triq com­bi­na­tion stud­ies.

As of a Ju­ly 27 cut­off date, re­searchers not­ed a con­firmed com­plete re­sponse at the 18mg/kg dose lev­el and three par­tial re­spons­es in the 8 mg/kg lev­el (out of 33 evalu­able pa­tients), ac­cord­ing to the ES­MO da­ta. And in the ate­zolizum­ab com­bi­na­tion tri­al, four out of 29 evalu­able pa­tients achieved a con­firmed par­tial re­sponse at ac­tive dose lev­els.

“We’re sat­is­fied that we have da­ta for our rec­om­mend­ed Phase II dose and we’re now re­al­ly fo­cused on mo­bi­liz­ing for Phase II ini­ti­a­tion,” Yo­der said on Wednes­day, adding that the study is ex­pect­ed to launch this year.

Pieris $PIRS has worked for years on en­gi­neer­ing pro­teins that are lighter and more ver­sa­tile than an­ti­bod­ies, so that they can work where an­ti­bod­ies find their en­try barred. On Wednes­day, their stock was up 1.5%, pric­ing in at $2.71 per share.

“What sets our ap­proach apart from even oth­er im­muno-on­col­o­gy agents such as the check­point in­hibitors is that we are ag­o­niz­ing po­tent­ly in the tu­mor mi­croen­vi­ron­ment tu­mor-spe­cif­ic T cells by tar­get­ing 4-1BB,” Yo­der said. “What that does is it im­proves the meta­bol­ic fit­ness of T cells, and it caus­es al­so their pro­lif­er­a­tion.”

“You don’t just re­ac­ti­vate T cells, but you ex­pand them, and you can po­ten­tial­ly give them a lot more longevi­ty and more dura­bil­i­ty,” he added.

De­spite the par­tial clin­i­cal hold, Eli Lil­ly struck a col­lab­o­ra­tion deal with Pieris in Au­gust to fur­ther ad­vance PRS-343 stud­ies in com­bi­na­tion with its Cyra­mza and chemother­a­py pa­cli­tax­el for the sec­ond-line treat­ment of pa­tients with HER2-pos­i­tive gas­tric can­cer. Lil­ly agreed to sup­ply the ad­di­tion­al com­pounds and col­lab­o­rate on da­ta while Pieris pre­pared to ini­ti­ate Phase II.

That isn’t Pieris’ first Big Phar­ma pact. Back in 2017, As­traZeneca com­mit­ted up to $57.5 mil­lion to seed an R&D pact with Pieris, which was charged with tak­ing PRS-060 — an An­ti­calin against in­ter­leukin-4 re­cep­tor al­pha — in­to a Phase I asth­ma tri­al. And be­fore that, it inked a deal to work with Servi­er for PRS-332 and four more im­muno-on­col­o­gy pro­grams.

UP­DAT­ED: Mer­ck pulls Keytru­da in SCLC af­ter ac­cel­er­at­ed nod. Is the FDA get­ting tough on drug­mak­ers that don't hit their marks?

In what could be an early shot in the battle against drugmakers that whiff on confirmatory studies to support accelerated approvals, the FDA ordered Bristol Myers Squibb late last year to give up Opdivo’s approval in SCLC. Now, Merck is next on the firing line — are we seeing the FDA buckling down on post-marketing offenders?

Merck has withdrawn its marketing approval for PD-(L)1 inhibitor Keytruda in metastatic small cell lung cancer as part of what it describes as an “industry-wide evaluation” by the FDA of drugs that do not meet the post-marketing checkpoints on which their accelerated nods were based, the company said Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.

Bob Nelsen (Photo by Michael Kovac/Getty Images)

With stars aligned and cash in re­serve, Bob Nelsen's Re­silience plans a makeover at 2 new fa­cil­i­ty ad­di­tions to its drug man­u­fac­tur­ing up­start

Bob Nelsen’s new, state-of-the-art drug manufacturing initiative is taking shape.

Just 3 months after gathering $800 million of launch money, a dream team board and a plan to shake up a field where he found too many bottlenecks and inefficiencies for the era of Covid-19, Resilience has snapped up a pair of facilities now in line for a retooling.

The company has acquired a 310,000-square-foot plant in Boston from Sanofi along with a 136,000-square-foot plant in Ontario to add to a network which CEO Rahul Singhvi says is just getting started on building his company’s operations up. The Sanofi deal comes with a contract to continue manufacturing one of its drugs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.

Amit Munshi, Arena

One of Are­na's top drugs flops in a PhI­Ib study for IBS pain. But re­searchers tease out a pos­si­ble path for­ward as CEO ex­plores 's­trate­gic op­tion­s'

Four years ago, when Arena CEO Amit Munshi cut its ties to a troubled weight drug and doubled down on the pipeline, a cannabinoid receptor 2 agonist figured prominently in the biotech’s future. On Tuesday evening, however, Munshi’s high hopes for the drug took a nasty hit after it failed a Phase IIb study for patients with irritable bowel syndrome pain.

Put through a randomized pace with 273 patients, researchers said it flat failed the primary endpoint among the large group with abdominal pain. But they quickly went on to highlight subgroup data, always a tricky and controversial ploy, where they spotlighted a positive p value for patients with moderate to severe pain who received the high dose of the drug — one of 3 provided in the study.

Fi­bro­Gen shares skid low­er as a sur­prise ad­comm rais­es risks on roxa OK

FibroGen will likely have to delay its US rollout for roxadustat once again.

In an unexpected move, the FDA is convening its Cardiovascular and Renal Drugs Advisory Committee to review the NDA in an advisory committee meeting. The date is yet to be confirmed.

Just a few weeks ago, SVB Leerink analyst Geoffrey Porges predicted that the roxa approval could come ahead of the PDUFA date on March 20 — effusive despite already being let down once by the FDA’s extension of its review back in December. AstraZeneca, which is partnered with FibroGen on the chronic kidney disease-related anemia drug, disclosed regulators had requested further clarifying analyses of clinical data.

Pascal Soriot, AstraZeneca CEO (AP Images)

Pas­cal So­ri­ot cash­es in As­traZeneca’s chips on Mod­er­na for $1.2B cash in­jec­tion

While still working to prove its own Covid-19 vaccine, AstraZeneca has reportedly capitalized on the success of another.

The company has sold off its 7.7% stake in Moderna and turned it into $1.2 billion in cash, according to the Times, beefing up the reserves just as Pascal Soriot is wrapping up his $39 billion acquisition of Alexion and its rare disease pipeline.

AstraZeneca’s stock sale follows a similar move by Merck in December. But like its pharma brethren, the British giant is keeping its R&D collaborations with Moderna.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Feds clear the road for J&J to start de­liv­er­ing mil­lions of dos­es of their Covid-19 vac­cine — but frets linger about run­ner-up sta­tus

All the pieces needed to trigger a third wave of Covid-19 vaccine supply to start washing over the US fell neatly into place over the weekend.

After providing for a brief mime of regulatory judiciousness, the FDA stamped their emergency approval on J&J’s Covid-19 vaccine Saturday, adding to the Biden administration’s plan aimed at ending the pandemic in the near term — at least in the US. The CDC came through on Sunday with its stamp of approval and J&J is reportedly expected to start delivering vaccine sometime in the next few days.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.

Af­ter bail­ing on Covid-19 vac­cines, Mer­ck will team up with J&J to pro­duce its shot as part of un­usu­al Big Phar­ma pact

Merck took a big gamble when it opted to jump into the Covid-19 vaccine race late, and made an equally momentous decision to back out in late January. Now, looking to chip in on the effort, Merck reportedly agreed to team up with one of the companies that has already crossed the finish line.

President Joe Biden on Tuesday is expected to announce a partnership between drugmakers Merck and Johnson & Johnson to jointly produce J&J’s recombinant protein Covid-19 vaccine that received the FDA’s emergency use authorization Saturday, the Washington Post reported.

Ab­b­Vie tees up a biotech buy­out af­ter siz­ing up their Parkin­son's drug spun out of Ke­van Shokat's lab

AbbVie has teed up a small but intriguing biotech buyout after looking over the preclinical work it’s been doing in Parkinson’s disease.

The company is called Mitokinin, a Bay Area biotech spun out of the lab of UCSF’s Kevan Shokat, whose scientific explorations have formed the academic basis of a slew of startups in the biotech hub. One of Shokat’s PhD students in the lab, Nicholas Hertz, co-founded Mitokinin using their lab work on PINK1 suggesting that amping up its activity could play an important role in regulating the mitochondrial dysfunction contributing to Parkinson’s disease pathogenesis and progression.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.

Paul Sekhri

The next big biotech su­per­star? Paul Sekhri has some thoughts on that

It occasionally occurs to Paul Sekhri that if they pull this off, his company will be on the front page of the New York Times and a lead story in just about every major news outlet on the planet. He tries not to dwell on it, though.

“I just want to be laser-focused on getting to that point,” Sekhri says, before acknowledging, “Yes, it absolutely crossed my mind.”

Sekhri, a longtime biopharma executive with tenures at Sanofi and Novartis, is now entering year three as CEO of eGenesis, the biotech that George Church protégé Luhan Yang founded to genetically alter pigs so that they can be used for organ transplants. He led them through one megaround and has just closed another, raising $125 million from 17 different investors to push the first-ever (humanized) pig to human transplants into the clinic.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.